A comprehensive and critical review of the latest scientific advances in our understanding of the
    molecular genetics and biology of CLL and their application to the best management of the disease. The
    authors focus on diagnosis, prognosis, multifaceted treatment options, and complications. Among the
    diverse treatments considered are chemotherapy, autologous and allogenic transplantations,
    monoclonal  antibody therapy, immunotoxin therapy, gene therapy, and several new therapeutic
    strategies. Familial and juvenile chronic lymphocytic leukemia are also discussed.

          Softcover - ISBN-13: 978-1588290991,  Pub Date: Mar 2005


    "In summary, this book has served well its purpose in discussing all the fascinating aspects of  CLL as it explores thoroughly the literature, the basic research
    developments, and the accumulated data of clinical trials. This extensive work will be a great addition to medical libraries and will be enjoyed not only by researchers
    and clinicians, but by trainees as well".
    Book review, Leukemia Research, 2004;28:995.
    Elie G. Dib, M.D.
    James P. Wilmot Cancer Center, University of Rochester
    Rochester, NY

    The highlights? Aside from collating basic and diagnostic laboratory science with clinical advances into one textbook, I was impressed by the chapters on genetics
    and molecular biology of CLL, which synthesised much of the recent advances in pathogenesis and their prognostic relevance. In particular, the description of the
    division of CLL cases into those with somatic hypermutations in the variable region of the immunoglobulin heavy chain gene, which have an excellent prognosis, and
    those with unmutated VH genes, which have a poor prognosis. [This book] will appeal to haematologists interested in a comprehensive overview of this disease,
    particularly with the extensive bibliographies provided with all chapters. I will certainly be referring a lot to my copy in future.
    Book Review: Cancer Forum, Vol 28 issue 2, July 2004.
    Professor Ken Bradstock
    Chair Australian Leukaemia Study Group
    Head of Blood & Marrow, Transplant Service
    Westmead Hospital, Westmead, NSW

    “This book presents a comprehensive summary of what is known in CLL and future directions.… [it] will certainly be a very useful reference work for the practicing
    adult hematologist... A thoughtful preface by the editor, Guy Faguet, points to the limitations of the ‘cell-kill’ approach in achieving the ultimate aim of cure of the
    disease, but encourages clinicians and scientists to develop treatments targeted at known molecular and genetic defects… After an interesting in-depth historical
    perspective… sections follow on biology, genetics, and clinical aspects. The now well-characterized cytogenetic and molecular lesions in CLL are well covered, as
    are the heterogeneous origin of B-CLL cells, the pathogenesis of impaired cellular immune function, and the role of cytokines and soluble molecules. The chapters on
    new treatment strategies are the most stimulating, and include consideration of monoclonal antibody… immunotoxin… and gene therapy. There is a brief but important
    section on manipulation of apoptotic cell signaling pathways... The final chapter on treatment of younger patients explores the quest for cure in this age group…”
    Book Review: Pediatric Haematology-Oncology, 2004;21:683-684.
    Geoffrey P. Summerfield, D.M., FRCP, FRCPath,
    Consultant Haematologist/Senior Lecturer in Haematology, Queen Elizabeth Hospital, Gateshead, UK

    (This book) updates the state of the art of information on chronic lymphocytic leukemia (CLL), provided in seven sections, including Historical Perspective, Biology
    and Genetics, Clinical Diagnosis, Prognosis, Treatment, Complications, and Familial and Juvenile CLL… there is often overlap … Nevertheless, the volume provides a
    very comprehensive review of current information regarding the clinical disease, the immunologic aberrations that are pathognomonic of the disease, and the clinical
    implications, as well as new molecular and genetic findings and new treatment approaches...
    Book Review: Medical Oncology, vol. 22, no. 2, 211-212, 2005
    Janice P. Dutcher, MD
    OLM Comprehensive Cancer Center
    New York Medical College
    Bronx, NY 10466